In the future, we expect obesity care to become much more differentiated, and with BI 3034701, we aim to go beyond short-term weight loss and address both the biological and behavioral drivers of obesity. BI 3034701 is part of a broader portfolio of therapies being developed for people living with obesity or obesity and connected metabolic health conditions, which has multiple approaches under investigation, including survodutide, a dual glucagon/GLP-1 agonist
If you are considering Dihexa use, you must consult with a qualified healthcare professional, preferably one with neuropharmacology expertise
Plaintiff Geoffrey Symonds claims he developed NAION after using Ozempic for less than three months, from November 2021 to January 2022
Commercial demand for these APIs can reach tens or even hundreds of kilograms annually, and in some cases may approach metric-ton production levels
frequently asked questions Liposuction, Tummy Tuck, or Both: A Decision Snapshot Identifying the main concern is the single most important step
DripVitals routes around the queue
